Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent~* 40 - 80 years of age~* Clinical history of COPD with airflow limitation that is not fully reversible~* Females of non-child bearing potential or females of child bearing potential with negative pregnancy test; and acceptable contraceptive methods~* Current/former smokers with at least a 10 pack-year history of cigarette smoking~* A measured post- bronchodilator FEV1/FVC ratio of \< or = 0.70~* A measured post- bronchodilator FEV1 \> or = 750ml or 30% predicted and \< or = 80% of predicted normal values~* Able to change COPD treatment as required by protocol~Exclusion Criteria:~* Women who are pregnant or lactating~* Primary diagnosis of asthma~* Alpha-1 antitrypsin deficiency as the cause of COPD~* Active pulmonary diseases~* Prior lung volume reduction surgery~* Abnormal chest X-ray (or CT scan) not due to the presence of COPD~* Hospitalized due to poorly controlled COPD within 3 months of Screening~* Clinically significant medical conditions that preclude participation in the study (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma, symptomatic prostatic hypertrophy)~* Cancer that has not been in complete remission for at least 5 years~* Treatment with investigational study drug or participation in another clinical trial or study within the last 30 days or 5 half lives~Other protocol defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Inhaled PT003 (Dose 1) (Type: EXPERIMENTAL): PT003 MDI Dose 1
- Inhaled PT003 (Dose 2) (Type: EXPERIMENTAL): PT003 MDI Dose 2
- Inhaled PT005 (Dose 1) (Type: EXPERIMENTAL): PT005 MDI Dose 1
- Inhaled PT005 (Dose 2) (Type: EXPERIMENTAL): PT005 MDI Dose 2
- Inhaled Placebo (Type: PLACEBO_COMPARATOR): Placebo MDI
- Tiotropium bromide 18 μg (Spiriva Handihaler®) (Type: ACTIVE_COMPARATOR): Tiotropium Bromide inhalation powder
- Formoterol Fumarate 12 μg (Foradil® Aerolizer®) (Type: ACTIVE_COMPARATOR): Formoterol fumarate inhalation powder 12 μg
- Inhaled PT001 (Dose 1) (Type: EXPERIMENTAL): PT001 MDI Dose 1

Based on this trial design, predict the completion outcome and termination type (if applicable).